Literature DB >> 11061498

Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism.

V Kantorovich1, M A Gacad, L L Seeger, J S Adams.   

Abstract

Two hundred and twenty-nine consecutive subjects, 202 women and 27 men, referred for evaluation of osteoporosis or low bone mineral density (BMD) had serum measurements of immunoreactive PTH (iPTH) and 25-hydroxyvitamin D (25OHD) performed. Fifteen individuals (mean age +/- SE, 75+/-2.4 yr) had depressed serum 25OHD (<15 pg/mL) and concomitantly elevated (>65 pg/mL) iPTH levels. After successful treatment of vitamin D insufficiency in all subjects, iPTH remained inappropriately high or frankly elevated in 5, describing a 2.2% prevalence rate of coexistent primary hyperparathyroidism and vitamin D insufficiency in our population. Despite persistent primary hyperparathyroidism, normalization of serum 25OHD levels in these 5 subjects increased their BMD at an annual rate of 6.3% and 8.2% in spine and hip, respectively. Our results suggest that coexistent vitamin D insufficiency can obscure the diagnosis of primary hyperparathyroidism and, when treated effectively, can result in substantial short-terms gains in BMD despite persistence of the inappropriate production of PTH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061498     DOI: 10.1210/jcem.85.10.6909

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

Review 1.  Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada.

Authors:  David A Hanley; Ann Cranney; Glenville Jones; Susan J Whiting; William D Leslie; David E C Cole; Stephanie A Atkinson; Robert G Josse; Sidney Feldman; Gregory A Kline; Cheryl Rosen
Journal:  CMAJ       Date:  2010-07-12       Impact factor: 8.262

2.  Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis.

Authors:  Michael P Boyle; Michelle L Noschese; Sharon L Watts; Marsha E Davis; Shane E Stenner; Noah Lechtzin
Journal:  Am J Respir Crit Care Med       Date:  2005-04-28       Impact factor: 21.405

3.  A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism.

Authors:  P Boudou; F Ibrahim; C Cormier; E Sarfati; J C Souberbielle
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

4.  Multifactorial risk profile for bone fractures in primary hyperparathyroidism.

Authors:  Erik Nordenström; Johan Westerdahl; Birger Lindergård; Pia Lindblom; Anders Bergenfelz
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

5.  Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation.

Authors:  Marcella D Walker; Elaine Cong; James A Lee; Anna Kepley; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2015-06-16       Impact factor: 5.958

6.  Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.

Authors:  R Cesareo; E Di Stasio; F Vescini; G Campagna; R Cianni; V Pasqualini; F Romitelli; F Grimaldi; S Manfrini; A Palermo
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507

7.  Effects of High-Dose Vitamin D2 Versus D3 on Total and Free 25-Hydroxyvitamin D and Markers of Calcium Balance.

Authors:  Albert Shieh; Rene F Chun; Christina Ma; Sten Witzel; Briana Meyer; Brandon Rafison; Leon Swinkels; Tonnie Huijs; Sam Pepkowitz; Brett Holmquist; Martin Hewison; John S Adams
Journal:  J Clin Endocrinol Metab       Date:  2016-05-18       Impact factor: 5.958

8.  Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.

Authors:  Prakash Chandra; José Nilo G Binongo; Thomas R Ziegler; Lynn E Schlanger; Wenli Wang; James T Someren; Vin Tangpricha
Journal:  Endocr Pract       Date:  2008 Jan-Feb       Impact factor: 3.443

9.  Management of hypovitaminosis D in patients with primary hyperparathyroidism.

Authors:  M S Rathi; S Gonzalez; D Wright; N R Ellis; S R Peacey
Journal:  J Endocrinol Invest       Date:  2014-02-11       Impact factor: 4.256

Review 10.  Vitamin D therapy.

Authors:  Jordan L Geller; John S Adams
Journal:  Curr Osteoporos Rep       Date:  2008-03       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.